Mupirocin
Centany, Mupirocin (mupirocin) is a small molecule pharmaceutical. Mupirocin was first approved as Bactroban on 1987-12-31. It is used to treat bacterial infections and impetigo in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Centany, Mupirocin (discontinued: Bactroban, Mupirocin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bactroban | New Drug Application | 2012-10-24 |
| centany | 2007-02-13 | |
| dermacinrx clorhexacin | unapproved drug other | 2020-11-11 |
| dermawerx surgical plus pak | ANDA | 2015-12-09 |
| levocetirizine dihydrochloride 2% / mupirocin 2% / triamcinolone acetonide 0.025% | unapproved drug other | 2019-05-14 |
| lidocaine 2% / mupirocin 2% | unapproved drug other | 2019-05-14 |
| metronidazole 1% / mupirocin 2% / | unapproved drug other | 2019-05-14 |
| metronidazole 1% / mupirocin 2% | unapproved drug other | 2019-05-14 |
| mupirocin | ANDA | 2024-10-24 |
| nusurgepak surgical prep/carepak | ANDA | 2020-06-22 |
Show 1 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| impetigo | EFO_1000714 | D007169 | L01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX09: Mupirocin
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AX: Other nasal preparations in atc
— R01AX06: Mupirocin
HCPCS
No data
Clinical
Clinical Trials
98 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Staphylococcal infections | D013203 | — | A49.01 | 1 | 3 | 1 | 11 | 16 | 32 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | 4 | 11 | 16 | 32 |
| Communicable diseases | D003141 | — | — | — | — | 4 | 10 | 14 | 28 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | 1 | 2 | 4 | 8 | 15 |
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | 1 | 5 | 9 | 15 |
| Surgical wound infection | D013530 | — | — | — | — | 3 | 4 | 6 | 13 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | — | 1 | 1 | 6 | 8 |
| Infectious skin diseases | D012874 | — | — | — | — | 1 | 1 | 5 | 7 |
| Abscess | D000038 | EFO_0003030 | — | — | — | — | 1 | 4 | 5 |
| Rhinosinusitis | D000096825 | — | — | 1 | 2 | 1 | 1 | — | 4 |
Show 22 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Impetigo | D007169 | EFO_1000714 | L01 | 1 | 2 | 2 | — | 1 | 5 |
| Radiodermatitis | D011855 | — | L58 | — | 2 | 1 | — | — | 2 |
| Hereditary hemorrhagic telangiectasia | D013683 | — | I78.0 | — | — | 1 | — | — | 1 |
| Epistaxis | D004844 | EFO_0003895 | R04.0 | — | — | 1 | — | — | 1 |
| Telangiectasis | D013684 | — | — | — | — | 1 | — | — | 1 |
| Nasopharyngeal carcinoma | D000077274 | — | — | — | — | 1 | — | — | 1 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | — | 1 | — | — | 1 |
| Nasopharyngeal neoplasms | D009303 | — | — | — | — | 1 | — | — | 1 |
| Mucositis | D052016 | EFO_1001898 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 3 | — | — | 1 | 4 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | 1 | 2 |
| Sinusitis | D012852 | EFO_0007486 | J32 | 1 | 1 | — | — | — | 1 |
| Staphylococcus | D013210 | — | — | — | 1 | — | — | — | 1 |
| Critical illness | D016638 | — | — | — | 1 | — | — | — | 1 |
| Hemangioma | D006391 | — | D18.0 | — | 1 | — | — | — | 1 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | — | 1 |
| Port-wine stain | D019339 | — | Q82.5 | — | 1 | — | — | — | 1 |
| Capillary hemangioma | D018324 | — | Q82.5 | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Furunculosis | D005667 | — | L02.92 | — | — | — | — | 3 | 3 |
| Wound healing | D014945 | GO_0042060 | — | — | — | — | — | 2 | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
| Photochemotherapy | D010778 | — | — | — | — | — | — | 1 | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Infertility | D007246 | HP_0000789 | — | — | — | — | — | 1 | 1 |
| Musculoskeletal diseases | D009140 | — | — | — | — | — | — | 1 | 1 |
| Multiple drug resistance | D018432 | — | — | — | — | — | — | 1 | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | — | — | — | 1 | 1 |
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mupirocin |
| INN | mupirocin |
| Description | Mupirocin is an alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections. It has a role as a bacterial metabolite, an antibacterial drug and a protein synthesis inhibitor. It is a monocarboxylic acid, a member of oxanes, an epoxide, a secondary alcohol, a triol and an alpha,beta-unsaturated carboxylic ester. It is a conjugate acid of a mupirocin(1-). |
| Classification | Small molecule |
| Drug class | t-RNA synthetase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 12650-69-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL719 |
| ChEBI ID | 7025 |
| PubChem CID | 446596 |
| DrugBank | DB00410 |
| UNII ID | D0GX863OA5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Mupirocin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,087 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,692 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use